-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Insider Selling: Kezar Life Sciences, Inc. (NASDAQ:KZR) Major Shareholder Sells $41,514.06 in Stock
Insider Selling: Kezar Life Sciences, Inc. (NASDAQ:KZR) Major Shareholder Sells $41,514.06 in Stock
Kezar Life Sciences, Inc. (NASDAQ:KZR – Get Rating) major shareholder Morningside Venture Investment sold 6,114 shares of the firm's stock in a transaction dated Tuesday, January 17th. The stock was sold at an average price of $6.79, for a total transaction of $41,514.06. Following the completion of the sale, the insider now owns 5,872,993 shares of the company's stock, valued at approximately $39,877,622.47. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Major shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.
Morningside Venture Investment also recently made the following trade(s):
Get Kezar Life Sciences alerts:- On Thursday, January 12th, Morningside Venture Investment sold 5,000 shares of Kezar Life Sciences stock. The stock was sold at an average price of $6.77, for a total transaction of $33,850.00.
- On Thursday, January 5th, Morningside Venture Investment sold 12,162 shares of Kezar Life Sciences stock. The shares were sold at an average price of $6.97, for a total transaction of $84,769.14.
Kezar Life Sciences Stock Performance
Shares of KZR opened at $6.42 on Friday. The company has a current ratio of 31.15, a quick ratio of 31.15 and a debt-to-equity ratio of 0.03. The firm has a market cap of $438.99 million, a PE ratio of -6.36 and a beta of 0.23. Kezar Life Sciences, Inc. has a 12 month low of $4.30 and a 12 month high of $18.55. The stock has a fifty day moving average price of $7.06 and a 200-day moving average price of $8.35.
Kezar Life Sciences (NASDAQ:KZR – Get Rating) last issued its quarterly earnings results on Thursday, November 10th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.01. Equities research analysts predict that Kezar Life Sciences, Inc. will post -1.03 earnings per share for the current fiscal year.Wall Street Analyst Weigh In
Separately, Wells Fargo & Company decreased their target price on Kezar Life Sciences from $17.00 to $14.00 and set an "overweight" rating for the company in a research report on Tuesday, January 3rd.
Institutional Investors Weigh In On Kezar Life Sciences
Large investors have recently made changes to their positions in the stock. BlackRock Inc. grew its stake in Kezar Life Sciences by 14.7% in the 3rd quarter. BlackRock Inc. now owns 4,104,929 shares of the company's stock valued at $35,343,000 after acquiring an additional 525,139 shares during the period. State Street Corp lifted its stake in Kezar Life Sciences by 381.3% in the 3rd quarter. State Street Corp now owns 3,537,701 shares of the company's stock valued at $30,460,000 after buying an additional 2,802,611 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Kezar Life Sciences by 22.8% in the 3rd quarter. Vanguard Group Inc. now owns 2,993,207 shares of the company's stock worth $25,771,000 after buying an additional 556,020 shares during the last quarter. Victory Capital Management Inc. increased its stake in Kezar Life Sciences by 58.0% during the 2nd quarter. Victory Capital Management Inc. now owns 2,770,098 shares of the company's stock worth $22,909,000 after buying an additional 1,017,391 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C acquired a new position in shares of Kezar Life Sciences during the second quarter valued at approximately $11,735,000. 84.03% of the stock is owned by hedge funds and other institutional investors.
About Kezar Life Sciences
(Get Rating)
Kezar Life Sciences, Inc is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco and California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J.
See Also
- Get a free copy of the StockNews.com research report on Kezar Life Sciences (KZR)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
科萨生命科学公司(纳斯达克代码:KZR-GET评级)的大股东晨兴风险投资公司在1月17日(星期二)的交易中出售了6,114股该公司股票。该股以6.79美元的平均价格出售,总成交金额为41514.06美元。出售完成后,这位内部人士现在拥有该公司5872,993股股票,价值约39,877,622.47美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可在以下网址获得此超链接。持有公司10%或以上股份的大股东必须披露他们在美国证券交易委员会上的销售和购买情况。
晨兴风险投资最近还进行了以下交易:
到达凯撒生命科学警报:- 1月12日,星期四,晨兴风险投资公司出售了5000股凯撒生命科学公司的股票。该股以6.77美元的平均价格出售,总成交金额为33,850.00美元。
- 1月5日,星期四,晨兴风险投资公司出售了12,162股凯撒生命科学公司的股票。这些股票以6.97美元的平均价格出售,总成交金额为84,769.14美元。
科萨生命科学公司股票表现
KZR的股票上周五开盘报6.42美元。该公司的流动比率为31.15,速动比率为31.15,债务权益比率为0.03。该公司市值为4.3899亿美元,市盈率为-6.36,贝塔系数为0.23。Kezar Life Science,Inc.的12个月低点为4.30美元,12个月高位为18.55美元。该股的50日移动均价为7.06美元,200日移动均价为8.35美元。
科萨生命科学(纳斯达克:KZR-GET评级)最近一次发布季度收益报告是在11月10日(星期四)。该公司公布本季度每股收益(0.25美元),比普遍预期的(0.26美元)高出0.01美元。股票研究分析师预测,Kezar Life Science,Inc.将公布本财年每股收益为1.03美元。华尔街分析师也加入进来
另外,富国银行将Kezar Life Science的目标价从17.00美元下调至14.00美元,并在1月3日(周二)的一份研究报告中为该公司设定了“增持”评级。
机构投资者看好Kezar生命科学
大型投资者最近对他们在该股的头寸进行了调整。贝莱德股份有限公司在第三季度增持了科萨生命科学14.7%的股份。贝莱德股份有限公司在此期间增持了525,139股,目前持有该公司4,104,929股股票,价值35,343,000美元。道富集团在第三季度增持了381.3%的凯撒生命科学股份。道富银行目前持有3,537,701股该公司股票,价值30,46万美元,上一季度又购买了2,802,611股。先锋集团(Vanguard Group Inc.)在第三季度增持了Kezar Life Science 22.8%的股份。先锋集团目前持有该公司2,993,207股股票,价值25,771,000美元,上一季度又购买了556,020股。胜利资本管理公司在第二季度增持了58.0%的凯撒生命科学股份。胜利资本管理公司现在持有2,770,098股该公司股票,价值22,909,000美元,该公司在上个季度又购买了1,017,391股。最后,Deerfield Management Company L.P.C系列在第二季度收购了价值约11,735,000美元的Kezar生命科学公司的新股票。84.03%的股票由对冲基金和其他机构投资者持有。
关于凯撒生命科学
(获取评级)
Kezar生命科学公司是一家临床阶段的生物制药公司,致力于开发新型小分子疗法,用于治疗旧金山南部和加利福尼亚州的自身免疫和癌症。其产品线包括KZR-616、KZR-261和KZR-TBD。该公司由约翰·福勒、克里斯托弗·J。
另请参阅
- 免费获取StockNews.com关于Kezar生命科学(KZR)的研究报告
- 市场回顾周-1/16-1/20
- Old Dominion是否表明Trucking正在踩刹车?
- 诺德斯特龙对零售业降价的担忧
- 埃克森美孚股票:在Buy Point附近
- 高股息率的必和必拓认为中国推动了23年的增长
接受《Kezar生命科学日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Kezar生命科学和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧